Drug Profile
Research programme: Kaposi's sarcoma-associated herpesvirus-mediated cancer therapies - Vironika
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Vironika
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA
- 18 Jul 2016 Research programme: Kaposi's sarcoma-associated herpesvirus-mediated cancer therapies - Vironika is available for licensing as of 18 Jul 2016. http://www.vironika.com/
- 18 Jul 2016 Early research in Cancer in USA (unspecified route)